文献速递白血病MDS 与骨髓增殖性肿瘤

TP53突变型髓系恶性肿瘤的基因组图谱

Genomic landscape of TP53-mutated myeloid malignancies.
PubMed 文献 · Blood Adv · 2023-01-01

对42例TP53突变的急性髓系白血病(AML)/骨髓增生异常综合征(MDS)病例及配对正常组织行全基因组测序,发现全基因组测序可准确判定TP53等位基因状态,使12%的病例由单等位基因重分类为多打击;同时揭示ETV6表达降低、NF1突变富集及端粒含量增高等独特基因组特征。

要点

  • 全基因组测序可准确判定TP53等位基因状态,使12%的病例由单等位基因重分类为多打击。
  • TP53突变型AML/MDS几乎均存在ETV6表达降低,可源于基因缺失或推测的表观遗传沉默。
  • TP53突变型AML中NF1突变高度富集,45%的病例存在1个NF1拷贝缺失,17%存在双等位基因突变。

核心结论

  • TP53突变型髓系恶性肿瘤具有独特的基因组特征,包括染色质碎裂和结构变异高发、NF1和ETV6等独特基因频繁作为协同事件参与、以及端粒维持改变的证据。

研究设计与样本

  • 对42例TP53突变的急性髓系白血病(AML)/骨髓增生异常综合征(MDS)病例及配对正常组织行全基因组测序(WGS)。

主要发现

  • 全基因组测序准确判定TP53等位基因状态,使12%的病例由单等位基因重分类为多打击。
  • 非整倍体和染色质碎裂与大多数TP53突变型癌症共有,但特定染色体异常因癌症类型而异,提示对组织来源的依赖。
  • TP53突变型AML/MDS几乎所有病例均存在ETV6表达降低,可源于基因缺失或推测的表观遗传沉默。
  • 在AML队列中NF1突变高度富集,45%的病例存在1个NF1拷贝缺失,17%存在双等位基因突变。
  • TP53突变型AML的端粒含量高于其他AML亚型,并在染色体间质区域检测到异常端粒序列。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TP53-mutated myeloid malignancies are associated with complex cytogenetics and extensive structural variants, which complicates detailed genomic analysis by conventional clinical techniques. We performed whole-genome sequencing (WGS) of 42 acute myeloid leukemia (AML)/myelodysplastic syndromes (MDS) cases with paired normal tissue to better characterize the genomic landscape of TP53-mutated AML/MDS. WGS accurately determines TP53 allele status, a key prognostic factor, resulting in the reclassification of 12% of cases from monoallelic to multihit. Although aneuploidy and chromothripsis are shared with most TP53-mutated cancers, the specific chromosome abnormalities are distinct to each cancer type, suggesting a dependence on the tissue of origin. ETV6 expression is reduced in nearly all cases of TP53-mutated AML/MDS, either through gene deletion or presumed epigenetic silencing. Within the AML cohort, mutations of NF1 are highly enriched, with deletions of 1 copy of NF1 present in 45% of cases and biallelic mutations in 17%. Telomere content is increased in TP53-mutated AMLs compared with other AML subtypes, and abnormal telomeric sequences were detected in the interstitial regions of chromosomes. These data highlight the unique features of TP53-mutated myeloid malignancies, including the high frequency of chromothripsis and structural variation, the frequent involvement of unique genes (including NF1 and ETV6) as cooperating events, and evidence for altered telomere maintenance.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Abel HJ, Oetjen KA, Miller CA, et al. Genomic landscape of TP53-mutated myeloid malignancies. Blood Adv. 2023. PMID: 37339484. doi:10.1182/bloodadvances.2023010156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。